GlobeImmune (GBIM) Announces GS-4774 Phase 2 in HBV Missed Primary Endpoint
Tweet Send to a Friend
GlobeImmune, Inc. (NASDAQ: GBIM) announced top line results from the GS-4774 Phase 2 study in patients with chronic hepatitis B ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
